MedTrace Logo

Mass Balance Study of [14C]JAB-21822

NCT05920941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-04-04

No results posted yet for this study

Summary

Mass Balance Study of \[14C\]JAB-21822 in China Healthy Subjects

Conditions

  • Mass Balance Study in Healthy Subjects

Interventions

DRUG

[14C]JAB-21822

Single oral administration of Carbon-14 labeled JAB-21822 800 mg/100 μCi on empty stomach

Sponsors & Collaborators

  • Allist Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Miao Liyan doctor of pharmacy · The First Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-08
Primary Completion
2023-08-09
Completion
2023-08-09

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05920941 on ClinicalTrials.gov